Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [19] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [20] - Adjusted earnings per share for Q4 2025 was $0.80, a 15% increase from 2024, exceeding guidance [19] - Full year 2025 adjusted earnings per share was $3.06, growing 22% versus 2024, also exceeding guidance [20] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [21] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [5] - Endoscopy achieved organic growth of 8% in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [5] - Neuromodulation grew 10% in Q4 and 8% for the full year, with the brain franchise showing low double-digit growth [6] - Cardiovascular segment delivered 16% growth operationally in Q4 and 22% operationally for the full year [7] - Watchman business grew 29% in Q4 and strong double-digit growth for the full year, driven by concomitant procedures [13] Market Data and Key Metrics Changes - U.S. market grew 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [3] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [4] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [3] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [4] - Strategic acquisitions, including Nalu Medical and Valencia Technologies, are aimed at enhancing the company's portfolio in neuromodulation and urology [24][25] - The company is focused on expanding its pain portfolio and enhancing operational efficiencies through new product launches and partnerships [7][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving organic growth of 10%-11% for 2026, with adjusted EPS growth of 12%-14% [27][28] - The company expects to maintain a strong market position despite competitive pressures, particularly in the EP segment [34][45] - Management highlighted the importance of upcoming clinical trial results, particularly for the Watchman product, which could significantly impact growth [81] Other Important Information - The company expects full-year free cash flow to be approximately $4.2 billion for 2026, with a target conversion rate of 70%-80% [24] - The adjusted tax rate for 2026 is forecasted to be around 12.5% [27] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management noted that EP grew 35% in Q4, exceeding internal targets, and Watchman grew 29%, indicating strong market performance despite concerns [33][36] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials and emphasized robust uptake of Watchman procedures [41] Question: Expectations for EP growth in 2026 - Management expects EP growth to exceed 15%, driven by new product approvals and market expansion [45] Question: Capacity issues in EP labs - Management acknowledged capacity constraints but emphasized ongoing efforts to build out ASCs and repurpose cath labs to alleviate wait times [72] Question: Confidence in long-term growth targets - Management remains confident in achieving 10%+ organic revenue growth through 2028, supported by strategic acquisitions and market leadership [86]

Core Viewpoint - Microelectrophysiology (688351.SH) has demonstrated strong growth in Q1 2025, with significant increases in revenue and net profit, indicating robust performance and development potential in the electrophysiology market [1] Financial Performance - In Q1 2025, the company achieved revenue of 104 million yuan, a year-on-year increase of 16.77% - The net profit attributable to shareholders reached 17.87 million yuan, up 328.63% year-on-year - The net profit after deducting non-recurring items also turned positive, amounting to 12.56 million yuan [1] Product Development and Commercialization - The company has completed the commercialization of PFA and has three products in the "green channel" for expedited approval - By 2024, over 30 registered products have been developed around the Columbus® 3D cardiac electrophysiology mapping system, with more than 70,000 surgeries performed using the 3D ablation series [2] - The PulseMagic™ pressure pulse catheter has entered the "green channel" for special review, with approval expected in 2025 [2] Technological Advancements - The EasyEcho™ intracardiac ultrasound catheter has also entered the "green channel," marking a significant innovation in high-end interventional imaging - This product utilizes intracardiac echocardiography technology for real-time, high-quality imaging without radiation, enhancing surgical precision and safety [3] Market Expansion and Growth Potential - The cardiac electrophysiology market is expected to reach 15.73 billion yuan in China by 2025, driven by increasing patient numbers and improved clinical outcomes - The PFA technology is anticipated to create a market space of over 10 billion yuan, reflecting significant growth opportunities [4] - The company plans to submit registrations for additional products in 2025, including pressure pulse ablation catheters and intracardiac ultrasound catheters [4] Internationalization Efforts - The company has expanded its international presence, with its 3D surgery covering 21 countries by 2024, and over 1,000 overseas surgeries performed using its pressure monitoring magnetic navigation RF ablation catheter [5] - The company has received CE certification for its cryo mapping catheter and cryo ablation devices, with further certifications expected for its magnetic navigation RF ablation catheter and high-density mapping catheter [6] Market Outlook - The global electrophysiology device market is projected to reach $14.49 billion by 2025 and could further increase to $32.45 billion by 2032, indicating a strong growth trajectory for the industry [6]